Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of multiple doses of LT3001 in acute ischemic stroke has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• LT3001

Snippet

Sponsor: Lumosa Therapeutics Co., Ltd. | Conditions: Acute Ischemic Stroke | Phase 2 | Status: COMPLETED | Results posted: 2025-12-26